Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell

Exclusion Criteria

• •1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection not responding to treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •2. Female participants who are pregnant or breastfeeding.
• •3. Unwilling or unable to follow protocol requirements.
• •4. Planned to receive any other anti-CMV therapy such as high dose acyclovir (500 mg/m2/dose intravenously every 8 hours or 800 mg orally 4 times a day) or high dose valacyclovir (2 grams three to four times daily or 2 grams three times daily) for the prophylaxis of CMV reactivation. Acyclovir or valacyclovir at lower doses for the prevention of HSV and VZV are allowed.
• •5. Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug.
• •6. Evidence for CMV infection defined as any positive CMV DNA qPCR test within 1 week prior to starting letermovir.
• •7. Child Pugh class C liver disease.